Acadia Pharmaceuticals: Nuplazid’s (Pimavanserin) Last Hurrah


  • Once a proud pipeline in a molecule, NUPLAZID (pimavanserin) rests on its old standby indication with one more waiting in the list.
  • Acadia’s Trofinetide in treatment of Rett syndrome is next up to bat with a PDUFA date of 03/12/2023.
  • Acadia needs a win badly to support its market cap.

Traveler with a backpack standing on a mountain peak above clouds. 3d render illustration

Orla/iStock via Getty Images

ACADIA (NASDAQ:ACAD) is an old standby that has been a serial disappointment. In this article I discuss the past, present, and future of its once promising mega-blockbuster therapy NUPLAZID (pimavanserin, selective serotonin inverse agonist). In the dreams of bulls.

Acadia's early focus on central nervous system disorders

Seeking Alpha

Acadia NUPLAZID revenues Q2, 2022

Acadia IR

NUPLAZID negative symptoms in schizophrenia status

Acadia IR

Q2, 2022 earnings presentation slide showing Trofinetide NDA

Acadia IR

Data by YCharts

Q2, 2022 financial highlights slide

Acadia IR

Disclosure: I/we have a beneficial long position in the shares of ACAD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I may buy or sell shares in any company mentioned over the next 72 hours.

Leave a Reply

Your email address will not be published. Required fields are marked *